Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2018-06-29 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-06-29 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-29 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement (Second Tranche Securities Purchase Agreement), creation of a financial obligation (Credit Agreement), unregistered sales of equity securities, appointment of a new director, and voting results from a special meeting. These are typical disclosures in an 8-K filing, which is a regulatory filing to inform investors of significant corporate events. The document is not an annual or quarterly report, earnings release, proxy statement, or other specific report type. It is a regulatory announcement of various corporate events and transactions. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial and contains detailed information, confirming it is not a brief announcement or certification only.
2018-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-27 English
FORM 3 SUBMISSION
Director's Dealing
2018-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-26 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.